Klaria Pharma publ : acquires Uppsalagruppen and becomes the owner of the patent that protects ’s technology platform

The transaction is structured as a share transfer agreement between the owners of Klaria and Uppsalagruppen, whereby all shares in Uppsalagruppen are acquired by Klaria. As consideration, Klaria has agreed to pay license fees and royalty payments on future earnings, substantially in line with the current license agreement between Klaria and Uppsalagruppen for Klaria's use of the patent.

The Board is of the opinion that the acquisition, in relation to the license agreement already in place between Klaria and Uppsalagruppen, does not significantly affect Klaria or its operations, except for Klaria obtaining exclusive ownership of the patent and thereby strengthening its IP-position. Uppsalagruppen had revenues of approximately 1,2 million SEK in 2018. The company had a net result of approximately -7 million SEK due almost exclusively to depreciation write downs. At the end of 2018, the company had assets of 170 thousand SEK.